SCHEDULE: Stonepine Capital Discloses AEON Biopharma Stake

Stonepine Capital Management, LLC and its affiliates have reported a 9.9% beneficial ownership in AEON Biopharma, Inc. Class A Common Stock.

Summary

• Stonepine Capital Management, LLC, along with Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico, have jointly filed a Schedule 13G.
• This filing indicates a beneficial ownership of 6,892,682 shares of AEON Biopharma, Inc. Class A Common Stock, representing 9.9% of the class.
• The reported holdings include 3,000,000 shares of Common Stock and warrants to acquire 6,000,000 shares, subject to a 9.99% beneficial ownership limitation.
• The percentage is calculated based on 68,995,818 shares outstanding as of July 15, 2026, following an offering.
• The reporting persons have jointly appointed Stonepine Capital Management, LLC as their agent for SEC filings.
• Each reporting person disclaims beneficial ownership beyond their pecuniary interest and membership in a group.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not provide operational or financial performance data for AEON Biopharma, Inc.

Positives

• Significant stake disclosed by Stonepine Capital, indicating investor confidence.
• Clear reporting of beneficial ownership and associated securities (stock and warrants).

Negatives

• The filing does not contain financial performance data or operational updates, limiting insight into the company's health.
• The beneficial ownership is subject to a 9.99% limitation, suggesting potential future adjustments.

Risks

• The 9.99% beneficial ownership limitation on warrants could impact future share acquisition plans.
• The filing does not provide details on the strategy behind this investment, leaving the purpose open to interpretation.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding AEON Biopharma's future performance. The future outlook is limited to the potential exercise of warrants, subject to ownership limitations.

Management Comments

• Each reporting person disclaims beneficial ownership of shares of Class A Common Stock except to the extent of that person's pecuniary interest therein.
• Each reporting person also disclaims beneficial ownership as defined in Rule 13d-3 under the Act, of any shares of Class A Common Stock covered by this Schedule 13G.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Stonepine Capital Management, LLC and its affiliates is a standard disclosure for significant institutional investors acquiring more than 5% of a company's voting stock. It signals a substantial investment position in AEON Biopharma, Inc., a company operating in the biopharmaceutical sector, which is characterized by high growth potential and significant regulatory hurdles.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially indicating confidence in the company's future prospects. However, the lack of operational details limits immediate impact.
• Management: May face increased scrutiny or engagement from Stonepine Capital due to their substantial ownership.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitoring of AEON Biopharma, Inc.'s operational and financial performance.
• Observation of any further filings or announcements from Stonepine Capital regarding their stake.
• Potential exercise of warrants by Stonepine Capital, subject to beneficial ownership limitations.

Key Dates

Keywords

AEON Biopharma, Stonepine Capital, Schedule 13G, Beneficial Ownership, Class A Common Stock, Warrants, SEC Filing, Investment